Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronavirus Infection Clear all
Completed Phase 2 Interventional Results available

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04492514
View directory record Official record
Conditions
COVID 19, SARS-CoV 2, Pneumonia
Interventions
Mavrilimumab, Placebo
Drug
Lead sponsor
Kristin Hudock
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

NCT04479358
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab, Standard of Care
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

NCT04652648
View directory record Official record
Conditions
Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Bryn Mawr Hospital
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Bryn Mawr, Pennsylvania • Paoli, Pennsylvania • Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting Not applicable Interventional

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

NCT03963622
View directory record Official record
Conditions
ARDS
Interventions
Respiratory Mechanics, Standard Ventilation Strategy
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting Not applicable Interventional

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

NCT04978571
View directory record Official record
Conditions
Post-Concussion Syndrome, COVID Long-Haul, COVID-19
Interventions
percutaneous electrical nerve-field stimulation, PENFS, percutaneous electrical nerve-field stimulation, PENFS (sham device), percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
Device
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
11 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits

NCT04758299
View directory record Official record
Conditions
COVID-19 Testing, Decision Making
Interventions
decision science-based design
Other
Lead sponsor
Barry Dewitt
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Early Phase 1 Interventional Results available

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

NCT05096884
View directory record Official record
Conditions
Tachycardia, Dyspnea, COVID-19
Interventions
Metoprolol Succinate
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational Results available

Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)

NCT04914364
View directory record Official record
Conditions
Covid19
Interventions
Balance assessments
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting Phase 1 Interventional

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314
View directory record Official record
Conditions
Influenza, Human+COVID-19
Interventions
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474
View directory record Official record
Conditions
COVID-19 Infection
Interventions
ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
69
States / cities
Canoga Park, California • Granada Hills, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

NCT04498247
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V591, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hollywood, Florida • Wichita, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05584176
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
2 Years and older
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
DeLand, Florida • Gainesville, Florida • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT04772170
View directory record Official record
Conditions
Influenza, Respiratory Virus, Coronavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 1 Interventional

Anti-SARS Cov-2 T Cell Infusions for COVID 19

NCT04401410
View directory record Official record
Conditions
SARS-CoV 2, Viral Infection, COVID 19
Interventions
Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 29, 2026, 9:47 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated No phase listed Observational

A Wearable, Battery-free Screening System for SARS-CoV-2, the Virus Causing COVID-19 Infection

NCT04807075
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational

Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients

NCT04953065
View directory record Official record
Conditions
Malignancies Multiple
Interventions
COVID-19 vaccine hesitancy and acceptance survey
Other
Lead sponsor
Monika Joshi
Other
Eligibility
18 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy

NCT03554265
View directory record Official record
Conditions
Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
Interventions
Somatropin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 29, 2026, 9:47 AM EDT